00864nas a2200205 4500008004100000022001400041245015700055210006900212260007300281300001200354490000700366100002600373700002800399700002200427700002000449700002400469700002000493700002000513856012500533 2009 eng d a1871-678400aDevelopment of mycoinsecticide for the control of insect pests: comparative evaluation of metarhizium isolates to identify strains for commercialization0 aDevelopment of mycoinsecticide for the control of insect pests c aPO BOX 211, 1000 AE AMSTERDAM, NETHERLANDSbELSEVIER SCIENCE BVcSEP aS88-S890 v251 aDeshpande, Mukund, V.1 aKulkarni, Shuklangi, A.1 aGhormade, Vandana1 aKapoor, Manisha1 aChavan, Santosh, B.1 aKulkarni, Grish1 aShouche, Yogesh uhttps://library.ncl.res.in/content/development-mycoinsecticide-control-insect-pests-comparative-evaluation-metarhizium-004670nas a2200205 4500008004100000245011000041210006900151260000800220300001400228490000700242520391400249100002104163700002204184700002404206700002304230700003404253700002704287700002204314856012804336 2019 eng d00a Development of a nano-gold immunodiagnostic assay for rapid on-site detection of invasive aspergillosis 0 aDevelopment of a nanogold immunodiagnostic assay for rapid onsit cSEP a1341-13520 v683 a

Introduction. Timely detection of invasive aspergillosis (IA) caused by fungal pathogens, i.e. Aspergillus fumigatus and Aspergillus flavus, in immunocompromised patients is crucial in preventing high mortality.

Aim. To develop a simple immunoassay for the detection of galactomannan (GM), an IA biomarker.

Methodology. GM from A. fumigatus and A. flavus clinical strains was purified and characterized by X-ray diffraction, IR spectroscopy and C-13/H-1 nuclear magnetic resonance (NMR) for polyclonal antibody (pAb) production in rabbits. An enzyme-linked immunosorbent assay (ELISA) was standardized using concanavalin A to capture Aspergillus GM and pAbs to detect it. Gold nanoparticles (AuNPs) were synthesized and conjugated to pAbs for the development of a dot-blot immunoassay. The developed dot-blot was evaluated with 109 clinical serum and bronchoalveolar lavage samples.

Results. Spectroscopy studies characterized the D-galactofuranosyl groups of GM responsible for the immune response and generation of pAbs. The ELISA employing pAbs showed a sensitivity of 1 ng ml(-1) for Aspergillus GM. Furthermore, a sensitive, visual, rapid dot-blot assay developed by the conjugation of pAbs to AuNPs (similar to 24 +/- 5 nm size, -36 +/- 2 mV zeta potential) had a detection limit of 1 pg ml(-1) in serum. The pAbs interacted with Aspergillus spp. but did not cross-react with other fungal pathogen genera such as Penicillium and Candida. Evaluation of the dot-blot with 109 clinical samples showed high sensitivity (80%) and specificity (93.2 %), with an overall assay accuracy of 89%.

Conclusion. The developed nano-gold immunodiagnostic assay has immense potential for practical use in rapid, specific and sensitive on-site diagnosis of IA, even under resource-limited settings.

1 aRaval, Komal, M.1 aGhormade, Vandana1 aRajamohanan, P., R.1 aChoudhary, Hansraj1 aRudramurthy, Shivaprakash, M.1 aChakrabarti, Arunaloke1 aPaknikar, Kishore uhttps://library.ncl.res.in/content/development-nano-gold-immunodiagnostic-assay-rapid-site-detection-invasive-aspergillosis02661nas a2200253 4500008004100000022001400041245017300055210006900228260000800297300001100305490000800316520177800324653001502102653001202117653002502129653001202154100001702166700001702183700002002200700001902220700002102239700002202260856012502282 2021 eng d a0927-776500aDesign and synthesis of a new topical agent for halting blood loss rapidly: a multimodal chitosan-gelatin xerogel composite loaded with silica nanoparticles and calcium0 aDesign and synthesis of a new topical agent for halting blood lo cFEB a1114540 v1983 a

Uncontrolled hemorrhage often causes death during traumatic injuries and halting exsanguination topically is a challenge. Here, an efficient multimodal topical hemostat was developed by (i) ionically crosslinking chitosan and gelatin with sodium tripolyphosphate for (ii) fabricating a robust, highly porous xerogel by lyophilization having 86.7 % porosity, by micro-CT and large pores similar to 30 mu m by SEM (iii) incorporating 0.5 mg synthesized silica nanoparticles (SiNPs, 120 nm size, -22 mV charge) and 2.5 mM calcium in xemgel composite that was confirmed by FTIR analysis with peaks at 3372, 986 and 788 cm(-1), respectively. XPS analysis displayed the presence of SiNPs (Si2p peak for silicon) and calcium (Ca2p1, Ca2p3 transition peaks) in the composite. Interestingly, in silico percolation simulation for composite revealed interlinked 800 mu m long-conduits predicting excellent absorption capacity and validated experimentally (640 % of composite dry weight). The composite achieved >16-fold improved blood clotting in vitro than commercial Celox and Gauze through multimodal interaction of its components with RBCs and platelets. The composite displayed good platelet activation and thrombin generation activities. It displayed high compressive strength (2.45 MPa) and withstood pressure during application. Moreover, xerogel composite showed high biocompatibility. In vivo application of xerogel composite to lethal femoral artery injury in rats achieved hemostasis (2.5 min) significantly faster than commercial Celox (3.3 min) and Gauze (4.6 min) and was easily removed from the wound. The gamma irradiated composite was stable till 1.5 yr. Therefore, the xerogel composite has potential for application as a rapid topical hemostatic agent.

10aHemostatic10aPolymer10asilica nanoparticles10aXerogel1 aPatil, Gokul1 aTorris, Arun1 aSuresha, P., R.1 aJadhav, Sachin1 aBadiger, Manohar1 aGhormade, Vandana uhttps://library.ncl.res.in/content/design-and-synthesis-new-topical-agent-halting-blood-loss-rapidly-multimodal-chitosan02786nas a2200241 4500008004100000022001400041245009500055210006900150260000900219300001600228490000700244520199000251100001602241700001802257700001802275700002102293700001902314700002302333700001902356700002202375700003002397856011702427 2025 eng d a2470-134300aDevelopment of novel ssDNA aptamers for detection of receptor-binding domain of SARS-COV-20 aDevelopment of novel ssDNA aptamers for detection of receptorbin cJUN  a23981-239920 v103 a

The highly virulent and transmissible SARS-CoV-2 causes COVID-19 and poses a global public health threat. Herein cloned, expressed, and the molecular weight of the receptor-binding domain (RBD) of the SARS-CoV-2 gene encoding protein was confirmed by SDS-PAGE electrophoresis and Western blot analysis. The pivotal aim is to develop single-stranded DNA (ssDNA) aptamers for the rapid detection of SARS-COV-2 infections in humans. In this investigation, a library of nine novel ssDNA aptamers was developed by several rounds of systematic evolution of ligands by an exponential enrichment approach and assessed by an enzyme-linked aptamer assay for binding affinity against RBD antigen (Ag). An in vitro assay resulted in a varied colorimetric signal that depends on the nature of aptamer. Quantitative determination of AptRBD3, AptRBD6, and AptRBD8 aptamers exhibited excellent binding affinity against Ag in the range of 5-10 ng/mL. The putative AptRBD3, AptRBD6, and AptRBD8 aptamers were converted into peptide sequences and docked against RBD, exhibiting good binding energy of -6.8, -6.3, and -7.1 kcal/mol respectively, which were recorded. Furthermore, docking studies of ssDNA aptamers were performed using HDOCK web server to ascertain the binding mechanism and docking score perceived as -389.74, -404.28, and -390.37. Despite this, we engineered a high-affinity AptRBD3.3 aptamer that formed a single and bulged loop, which improved binding affinity, resulted in a docking score of -361.56, and exhibited sensitivity at 4 ng of Ag of SARS-CoV-2. Moreover, computational modeling of AptRBD3.3 revealed an intriguing significant binding affinity with the RBD mutant SARS-CoV-2 S-UK variant (PDB ID: 7EDG) with a docking score of -350.21. In conclusion, the AptRBD3.3 aptamer can be used for the development of lateral flow device and electrochemical sensors for rapid, low-cost, and accurate detection of COVID-19 infection in humans for point of care diagnostics.

1 aAuti, Amogh1 aYadav, Pranay1 aBodkhe, Rahul1 aBhandari, Yogesh1 aVarma, Sanjana1 aChaudhari, Bhushan1 aRahi, Shraddha1 aGhormade, Vandana1 aVamkudoth, Koteswara, Rao uhttps://library.ncl.res.in/content/development-novel-ssdna-aptamers-detection-receptor-binding-domain-sars-cov-2